{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:19:23Z","timestamp":1792343963630,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jad.2019.12.023","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T02:03:24Z","timestamp":1576289004000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review"],"prefix":"10.1016","volume":"264","author":[{"given":"David S.","family":"Mathai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"2 Suppl","key":"10.1016\/j.jad.2019.12.023_bib0003","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1038\/sj.npp.1395318","article-title":"Serotonin and hallucinogens","volume":"21","author":"Aghajanian","year":"1999","journal-title":"Neuropsychopharmacol. Official Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0004","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0893-133X(99)00106-2","article-title":"Serotonin\u2013Glutamate interactions: a new target for antipsychotic drugs","volume":"21","author":"Aghajanian","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2019.12.023_bib0005","unstructured":"Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD). (n.d.). Retrieved July28, 2019, fromhttps:\/\/www.prnewswire.com\/news-releases\/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0006","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euroneuro.2019.02.005","article-title":"Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder","volume":"29","author":"Aust","year":"2019","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0007","first-page":"10","article-title":"Ketamine: review of its pharmacology and its use in pediatric anesthesia","volume":"46","author":"Bergman","year":"1999","journal-title":"Anesth. Prog."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2019.12.023_bib0009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hup.2545","article-title":"Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens","volume":"31","author":"Bouso","year":"2016","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress"},{"issue":"10","key":"10.1016\/j.jad.2019.12.023_bib0011","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1177\/0269881117725685","article-title":"Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders","volume":"31","author":"Castle","year":"2017","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/15622975.2016.1139747","article-title":"Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review","volume":"18","author":"Cooper","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2019.12.023_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry."},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"8","key":"10.1016\/j.jad.2019.12.023_bib0018","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jad.2019.12.023_bib0073","unstructured":"Evans, J.D., 1996. Straightforward Statistics for the Behavioral Sciences. Brooks\/Cole Publishing Company."},{"key":"10.1016\/j.jad.2019.12.023_bib0019","author":"Fava","year":"2018"},{"key":"10.1016\/j.jad.2019.12.023_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","author":"Fedgchin","year":"2019","journal-title":"The International Journal of Neuropsychopharmacology."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0021","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review","volume":"24","author":"Garcia-Romeu","year":"2016","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2019.12.023_bib0022","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.jad.2019.12.023_bib0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","volume":"61","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0026","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0027","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","article-title":"Ketamine-associated brain changes: a review of the neuroimaging literature","volume":"26","author":"Ionescu","year":"2018","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2019.12.023_bib0029","unstructured":"Jansen, K.L.R. (2001). Ketamine: dreams and realities. multidisciplinary association for psychedelic studies."},{"issue":"3","key":"10.1016\/j.jad.2019.12.023_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2045125317749456","article-title":"Alternatives to ketamine in depression: state-of-the-art and future perspectives","volume":"8","author":"Jelen","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0032","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoactive Drugs"},{"issue":"12","key":"10.1016\/j.jad.2019.12.023_bib0033","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2019.12.023_bib0034","first-page":"56","author":"Luckenbaugh","year":"2014"},{"issue":"3","key":"10.1016\/j.jad.2019.12.023_bib0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"key":"10.1016\/j.jad.2019.12.023_bib0037","series-title":"Where God and Science Meet: The Neurology of Religious Experience","author":"McNamara","year":"2006"},{"issue":"5","key":"10.1016\/j.jad.2019.12.023_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2019.12.023_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the Prisma statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0042","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2019.12.023_bib0043","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2017.11.088","article-title":"Dissociation after ketamine dosing: is the CADSS fit for purpose?","volume":"244","author":"Neehoff","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0044","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0045","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int. Psychiatry Clin."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0046","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0047","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"10.1016\/j.jad.2019.12.023_bib0048","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jad.2016.10.026","article-title":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","volume":"208","author":"Pennybaker","year":"2017","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2019.12.023_bib0049","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"The American Journal of Psychiatry.."},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0050","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"The American Journal of Psychiatry.."},{"issue":"5","key":"10.1016\/j.jad.2019.12.023_bib0051","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.12.023_bib0052","article-title":"The ketamine papers: Science, therapy, and transformation","author":"Ring","year":"2016","journal-title":"MAPS."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0053","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","article-title":"Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine","volume":"65","author":"Salvadore","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2019.12.023_bib0054","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano\u2010Higgins","year":"2016","journal-title":"Depress Anxiety"},{"issue":"9","key":"10.1016\/j.jad.2019.12.023_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044799","article-title":"Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action","volume":"7","author":"Scheidegger","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0056","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0058","first-page":"287","article-title":"Relationship of ketamine\u2019s antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.jad.2019.12.023_bib0059","unstructured":"SPRAVATOTM (esketamine) nasal spray, CIII Highlights of Prescribing Information. (2019, May). Retrieved fromhttps:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf."},{"issue":"4","key":"10.1016\/j.jad.2019.12.023_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S109285291300045X","article-title":"Mechanism of action of ketamine","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.jad.2019.12.023_bib0061","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jad.2019.12.023_bib0062","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","article-title":"Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the clinician administered dissociative state scale","volume":"227","author":"van Schalkwyk","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2019.12.023_bib0063","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JCP.0000000000000960","article-title":"Efficacy and safety of a rapid intravenous injection of ketamine 0.5mg\/kg in treatment-resistant major depression: An open 4-Week longitudinal study","volume":"38","author":"Vidal","year":"2018","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0064","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2019.12.023_bib0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacol. Official Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2019.12.023_bib0066","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"12","key":"10.1016\/j.jad.2019.12.023_bib0067","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2019.12.023_bib0068","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.jad.2019.12.023_bib0069","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/00023210-200620030-00003","article-title":"Ketamine: from medicine to misuse","volume":"20","author":"Wolff","year":"2006","journal-title":"CNS Drugs"},{"issue":"7604","key":"10.1016\/j.jad.2019.12.023_bib0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jad.2019.12.023_bib0071","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2019.12.023_bib0072","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719324747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719324747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:32:47Z","timestamp":1759023167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032719324747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":65,"alternative-id":["S0165032719324747"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.12.023","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}